Search Results for :


Castle Biosciences Launches Next-Generation Sequencing Panel DecisionDx-UMSeq for Uveal Melanoma

Friendswood, TX – January 8, 2018 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the launch of the DecisionDx®-UMSeq panel that uses next-generation sequencing (NGS) to identify somatic mutations in genes relevant to uveal melanoma (UM). The new test will complement Castle Biosciences’ standard-of-care DecisionDx®-UM gene expression … Read More


Frank Stokes

Frank Stokes has more than 20 years of experience in finance, including extensive experience leading capital formation for high-growth healthcare and life science companies.  Most recently he was CFO of Hammock Pharmaceuticals where he assisted in the initial capitalization of the company as well as the acquisition of Hammock’s foundational drug delivery technology.  Previously Frank … Read More


Castle Biosciences Announces the Appointment of Frank Stokes as Chief Financial Officer

Friendswood, TX – December 7, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the appointment of Frank Stokes as Chief Financial Officer (CFO). Mr. Stokes has extensive experience leading capital formation for high-growth companies, most recently as CFO of Hammock Pharmaceuticals and previously as a Senior … Read More


Castle Biosciences to Present at the Piper Jaffray 29th Annual Healthcare Conference

Friendswood, TX – November 20, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that Derek Maetzold, President and CEO will be presenting at the Piper Jaffray 29th Annual Healthcare Conference on Tuesday, November 28th, 2017 at 8:10 a.m. ET in New York City.
About Castle Biosciences
Read More


Watch the Replay of Federico Monzon, MD’s Presentation Webcast at the Cancer Research & Oncology Live Virtual Event

Catch the on-demand replay of “Personalizing Melanoma Management with Molecular Diagnostics” presented by Castle Biosciences’ Federico Monzon, MD. The presentation provides an overview of the use of molecular diagnostics in melanoma, from screening to monitoring therapy, and was part of a virtual event that focused on advancements in prevention, diagnosis and … Read More


New Publication Highlights First Prospective Performance Assessment of the DecisionDx-Melanoma Gene Expression Profile Test

Friendswood, TX – September 5, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the publication of the first prospective assessment of prognostic performance for the DecisionDx®-Melanoma test in a multi-center population of patients with cutaneous (skin) melanoma. The gene expression profile (GEP) test uses tumor biology … Read More


Castle Biosciences’ DecisionDx-Melanoma Test Performance Demonstrated in Newly Expanded Multicenter Cohort of 782 Patients

Friendswood, TX–August 29, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that results of the DecisionDx®-Melanoma prognostic test’s performance in a cumulative cohort of 782 patients with cutaneous melanoma were presented during the 23rd International Pigment Cell Conference (IPCC 2017) held in Denver, CO from August … Read More